{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/successfully-delivering-ultra-rare-disease-clinical-trial-competitive-landscape-0#webpage",
"url": "https://www.fortrea.com/insights/successfully-delivering-ultra-rare-disease-clinical-trial-competitive-landscape-0",
"name": "Successfully delivering an ultra-rare disease clinical trial in a competitive landscape",
"description": "This Fortrea case study explores how an ultra-rare disease clinical trial was successfully delivered within a competitive rare disease trial landscape during a global Phase III study for limb-girdle muscular dystrophy type 2I (LGMD2I). The study involved significant recruitment challenges related to limited patient populations, competing LGMD2I clinical trials, protocol modifications, and operational coordination across 21 sites in eight countries. The case study highlights how rare disease patient recruitment and patient recruitment for LGMD2I trials required a structured global recruitment strategy for rare disease studies combined with operational flexibility and early collaboration with investigative sites. Fortrea implemented an operational strategy for ultra-rare disease studies that included advocacy group engagement for recruitment, site relationship development, enrollment planning, and ongoing coordination across study stakeholders to support recruitment continuity throughout the trial lifecycle. By integrating rare disease patient enrollment strategy activities with global operational support and neuromuscular clinical trial management, the approach strengthened recruitment execution and supported timely delivery of the Phase III ultra-rare disease clinical trial."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Successfully delivering an ultra-rare disease clinical trial in a competitive landscape",
"item": "https://www.fortrea.com/insights/successfully-delivering-ultra-rare-disease-clinical-trial-competitive-landscape-0"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/successfully-delivering-ultra-rare-disease-clinical-trial-competitive-landscape-0#casestudy",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/successfully-delivering-ultra-rare-disease-clinical-trial-competitive-landscape-0#webpage"
},
"headline": "Delivering an Ultra-Rare Disease Clinical Trial in a Competitive Recruitment Landscape | Fortrea Case Study",
"description": "This Fortrea case study explores how an ultra-rare disease clinical trial was successfully delivered within a competitive rare disease trial landscape during a global Phase III study for limb-girdle muscular dystrophy type 2I (LGMD2I). The study involved significant recruitment challenges related to limited patient populations, competing LGMD2I clinical trials, protocol modifications, and operational coordination across 21 sites in eight countries. The case study highlights how rare disease patient recruitment and patient recruitment for LGMD2I trials required a structured global recruitment strategy for rare disease studies combined with operational flexibility and early collaboration with investigative sites. Fortrea implemented an operational strategy for ultra-rare disease studies that included advocacy group engagement for recruitment, site relationship development, enrollment planning, and ongoing coordination across study stakeholders to support recruitment continuity throughout the trial lifecycle. By integrating rare disease patient enrollment strategy activities with global operational support and neuromuscular clinical trial management, the approach strengthened recruitment execution and supported timely delivery of the Phase III ultra-rare disease clinical trial.",
"genre": "Case Study",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-02/ultra-rare-disease-clinical-trial-in-a-competitive-landscape.jpg"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-02-15",
"dateModified": "2025-02-15",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-02/ultra-rare%20disease%20clinical%20trial%20in%20a%20competitive%20landscape.pdf",
"encodingFormat": "application/pdf"
}
}
]
}